Table 1.
Clinical and Pathologic Features according to HIF1A Expression or EPAS1 (HIF-2α) Expression Status
| Clinical or pathologic feature | Total (N) | HIF1A expression
|
P value | EPAS1 expression
|
P value | ||
|---|---|---|---|---|---|---|---|
| (−) | (+) | (−) | (+) | ||||
| All cases | 731 | 589 | 142 | 373 | 322 | ||
| Sex | 0.058 | 0.0043 | |||||
| Male (HPFS) | 261 | 220 (37%) | 41 (29%) | 112 (30%) | 130 (40%) | ||
| Female (NHS) | 470 | 369 (63%) | 101 (71%) | 261 (70%) | 192 (60%) | ||
| Age (yr) | |||||||
| ≤59 | 148 | 116 (20%) | 32 (23%) | 0.74 | 80 (21%) | 56 (17%) | 0.40 |
| 60–69 | 307 | 250 (42%) | 57 (40%) | 152 (41%) | 139 (43%) | ||
| ≥70 | 276 | 223 (38%) | 53 (37%) | 141 (38%) | 127 (40%) | ||
| BMI | 0.90 | 0.021 | |||||
| <30 kg/m2 | 604 | 487 (83%) | 117 (82%) | 297 (80%) | 277 (86%) | ||
| ≥30 kg/m2 | 126 | 101 (17%) | 25 (18%) | 76 (20%) | 44 (14%) | ||
| Family history of colorectal cancer | 0.40 | 0.48 | |||||
| (−) | 560 | 455 (77%) | 105 (74%) | 290 (78%) | 243 (75%) | ||
| (+) | 171 | 134 (23%) | 37 (26%) | 83 (22%) | 79 (25%) | ||
| Tumor location | 0.80 | 0.21 | |||||
| Proximal colon (cecum to transverse) | 361 | 294 (51%) | 67 (48%) | 184 (50%) | 159 (50%) | ||
| Distal colon (splenic flexure to sigmoid) | 214 | 172 (30%) | 42 (30%) | 100 (27%) | 100 (32%) | ||
| Rectum | 142 | 112 (19%) | 30 (22%) | 83 (23%) | 56 (18%) | ||
| Stage | 0.069 | 0.28 | |||||
| I | 160 | 140 (24%) | 20 (14%) | 74 (20%) | 82 (26%) | ||
| II | 222 | 180 (31%) | 42 (30%) | 110 (29%) | 101 (31%) | ||
| III | 200 | 157 (27%) | 43 (30%) | 110 (29%) | 77 (24%) | ||
| IV | 108 | 77 (13%) | 31 (22%) | 58 (16%) | 44 (14%) | ||
| Unknown | 41 | 35 (5.9%) | 6 (4.2%) | 21 (5.6%) | 18 (5.6%) | ||
| Tumor grade | 0.36 | 0.0016 | |||||
| Low | 660 | 535 (91%) | 125 (89%) | 325 (88%) | 305 (95%) | ||
| High | 68 | 52 (8.9%) | 16 (11%) | 45 (12%) | 17 (5.3%) | ||
| Mucinous component | 0.26 | 0.11 | |||||
| 0% | 373 | 297 (57%) | 76 (62%) | 196 (60%) | 157 (54%) | ||
| >0% | 272 | 226 (43%) | 46 (38%) | 128 (40%) | 133 (46%) | ||
| Signet ring cell component | 0.24 | 0.16 | |||||
| 0% | 549 | 443 (89%) | 106 (93%) | 272 (88%) | 250 (92%) | ||
| >0% | 61 | 53 (11%) | 8 (7.0%) | 37 (12%) | 23 (8.4%) | ||
Percentage indicates the proportion of tumors with a specific clinical or pathologic feature in all patients or patients with a specific category of HIF1A or EPAS1 expression status. HPFS, Health Professionals Follow-Up Study; NHS, Nurses’ Health Study.